Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03728192
Other study ID # MAHER-MU-004-IEC/2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 7, 2016
Est. completion date July 13, 2018

Study information

Verified date October 2018
Source Meenakshi Ammal Dental College and Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study is an effort to investigate the hypothesis that in-vitro vitality and antiapoptotic effect of alcoholic crude extract of mangosteen on Oral cancer( H357) cell lines and Cevical cancer (HeLa) cell lines.


Description:

The oral and cervical cells were investigated by MTT (3-4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, DNA fragmentation detection by TUNEL (Terminal deoxynucleotidyl transferase-mediated d-UTP Nick End Labeling) assay and Apototic assay using Annexin V/FITC Kit.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date July 13, 2018
Est. primary completion date May 11, 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with oral squamous cell carcinoma

- Patients with cervical carcinoma

Exclusion Criteria:

• Patients with leukaemia

Study Design


Related Conditions & MeSH terms


Intervention

Other:
mangosteen extract
For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Meenakshi Ammal Dental College and Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary apoptotic potential of ethanolic extract of mangosteen pericarp on oral and cervical cancer cell lines via apoptotic assay Apoptosis assay was performed using Annexin V/FITC Kit (BD Biosciences, Catalog no. 556547), and the fluorescence intensities of FITC-conjugated annexin-V and Propidium iodide (PI) in cells were analyzed using flow cytometry. HeLa and H357 cells (1×106 cells/well) were seeded in a 6-well plate. The cells were allowed to adhere for 12 hrs, cultured in medium containing different concentrations of mangosteen extract for 48hr. The cells were then collected and washed twice with Phosphate buffer Saline, gently resuspended in 100µL annexinV-FITC binding buffer (1x) and incubated with 5µL annexinV-FITC in the dark for 10 min at 25°C. This was followed by centrifugation of cells at 2000 rpm for 5 min, and gently resuspended in 500µL annexinV-FITC binding buffer (1x) and 5µL PI was added in an ice bath, followed by immediate analysis by flow cytometry Cell Quest software (BD Biosciences). 48 hrs at base line
See also
  Status Clinical Trial Phase
Completed NCT04323852 - Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery? Phase 4
Not yet recruiting NCT06147960 - Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Recruiting NCT04431505 - Anaesthesia and Apoptosis
Completed NCT04607434 - Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury
Recruiting NCT01267786 - The Effect of Volatile Anesthetics Sevoflurane and Desflurane on Liver, Renal and Cardiovascular Systems During Liver Surgery Phase 4